On May 29, 2025, Synergy CHC Corporation completed a debt settlement with Knight Therapeutics International S.A., which included a $1,500,000 conversion into equity. Subsequently, on June 11, 2025, Synergy issued a pre-funded common stock purchase warrant to Knight, allowing the purchase of up to 428,570 shares of common stock. The aggregate exercise price was pre-funded, with a nominal exercise price of $0.00001 per share. The warrant may be exercised via "cashless exercise" by June 11, 2026, or upon the next sale of equity securities by the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.